← Back to searchRecruitingRecruiting
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
NCT06059690 · Jonsson Comprehensive Cancer Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Biologic Association Between Metabolic MR-PET and Tissue Measures of Glycolysis in Brain Tumors Visualization, Quantitation, and Targeting of Infiltrating Glioblastoma Cells With pH Sensitive Amine Chemical Exchange Saturation Transfer Magnetic Resonance Imaging-KL2TR001882
About this study
Patients who are scheduled for resection of glioblastoma multiforme (GBM) as part of standard care will be invited to take part in the study. All patients will undergo FDG-PET scan for the study using standard clinical imaging techniques, along with standard brain MRI plus up to approximately 15 minutes of investigational MR imaging sequences to permit calculation of \"glycolytic index\" as an experimental GBM imaging biomarker. Following pH measurements, the patient's clinical biopsy/tumor resection will take place as planned for clinical care. Tissue samples resected during the clinical procedure will be obtained and processed using immunohistochemistry techniques for further assessments, including RNA sequencing and bioenergetics analysis.
The current study will investigate the central hypothesis that biopsied tumor tissue undergoing high levels of glycolysis via RNA expression, protein expression, and bioenergetics analyses can be reliably detected, correlates with direct measure of tissue pH, and is strongly associated with a "glycolytic index" created by combining 18F-FDG PET, amine CEST-SAGE-EPI, perfusion MRI and diffusion MRI. In addition, the investigators will investigate whether metabolic differences identified from this imaging modality may identify infiltrating non-enhancing tumor cells.
FDG: 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose CEST: chemical exchange saturation transfer SAGE: spin and gradient echo EPI: echo planar imaging IHC: immuno-histochemical rCBF: regional cerebral blood flow rCBV: relative cerebral volume DSC: dynamic susceptibility contrast ADC: apparent diffusion coefficient MCT: Monocarboxylate transporters
Eligibility criteria
Inclusion Criteria:
* Age \> 18
* Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery
Exclusion Criteria:
* Patients who cannot obtain an MRI or FDG PET scan with contrast
* Those with ferromagnetic implanted devices that might produce a safety hazard (e.g. infusion pumps, pace makers, aneurysm clips, etc.) will be excluded from the study along with subjects with severe claustrophobia or who have severely compromised renal function (GFR \< 30).
Study design
Enrollment target: 50 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-09-06
Estimated completion: 2028-09-30
Last updated: 2025-10-08
Interventions
Diagnostic Test: pH Measurement of in vivo tissue
Primary outcomes
- • Glycolytic Index (two years)
- • Immunohistochemistry Expression of Glycolytic Molecules (two years)
Sponsor
Jonsson Comprehensive Cancer Center · other
With: Nitional institute of Health -National Center for Advancing Translational Sciences
Contacts & investigators
ContactRaksha Nagaraj · contact · RNagaraj@mednet.ucla.edu · 310-794-8995
ContactSaima Chaabane · contact · schaabane@mednet.ucla.edu · 310-794-8995
InvestigatorBenjamin Ellingson, PhD · principal_investigator, University of California at Los Angeles
All locations (1)
University of California at Los AngelesRecruiting
Los Angeles, California, United States